Key result
Intensive lipid lowering plus multivessel PCI resolves ischemia and lowers LDL-C in severe adolescent FH.
Why the study?
Although atherosclerotic cardiovascular disease is common in adults with familial hypercholesterolemia, events occurring during adolescence are rare.
Case Report (n=1)
This case highlights that aggressive, genetically unique forms of heterozygous familial hypercholesterolemia can cause premature ASCVD in adolescence, emphasizing the need for early detection, treatment, and cascade screening.
Consider ASCVD in symptomatic adolescents with FH; leaves open optimal early screening and intervention strategies.
BACKGROUND: Familial hypercholesterolemia is characterized by lifelong elevations in low-density lipoprotein cholesterol (LDL-C) that, when left untreated, markedly increase the risk of premature atherosclerotic cardiovascular disease (ASCVD). Although ASCVD is common in adults with familial hypercholesterolemia, events in adolescence are rare. CASE SUMMARY: A 14-year-old man presented with exertional chest pain and mild troponin elevation. Myocarditis was initially suspected, but the persistence of symptoms prompted advanced imaging, revealing multivessel ASCVD. LDL-C was severely elevated (9 mmol/L, 350 mg/dL). Atorvastatin and ezetimibe lowered LDL-C to ≤1.4 mmol/L (<55 mg/dL). Multivessel percutaneous coronary intervention resulted in resolution of symptoms and inducible ischemia. A heterozygous APOE p.(Leu167del) pathogenic variant was identified, an uncommon cause of heterozygous familial hypercholesterolemia (HeFH). Similarly severe dyslipidemia was identified in the 6-year-old brother. DISCUSSION: This particularly aggressive and genetically unique form of HeFH resulted in premature ASCVD from adolescence. TAKE-HOME MESSAGE: Early detection and treatment prevent catastrophic cardiovascular events in HeFH; cascade screening is essential for at-risk relatives.
No takes yet. Share an insight, caveat, or question.
Thorsen et al. (2026) conducted a case report in Severe multivessel coronary artery disease and familial hypercholesterolemia (n=1). Atorvastatin, ezetimibe, and multivessel percutaneous coronary intervention was evaluated on Resolution of symptoms and inducible ischemia, and LDL-C reduction. Atorvastatin, ezetimibe, and multivessel percutaneous coronary intervention lowered LDL-C to ≤1.4 mmol/L and resolved symptoms in a 14-year-old with severe familial hypercholesterolemia.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: